Regeneron have Identified Antibodies to Treat Coronavirus

Regeneron Pharmaceuticals Inc announces that it had identified hundreds of antibodies that could potentially treat the coronavirus.

Regeneron have Identified Antibodies to Treat Coronavirus

“We’ve identified hundreds of virus-neutralizing antibodies from our VelocImmune technology and are now selecting the top candidates for clinical testing,” Regeneron says in a tweet.

Regeneron Pharmaceuticals, Inc. today announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company’s VelocImmune® mice, which have been genetically-modified to have a human immune system. Regeneron has also isolated antibodies from humans who have recovered from COVID-19, in order to maximize the pool of potentially potent antibodies. From this large pool of candidates, Regeneron will select the top two antibodies for a ‘cocktail’ treatment based on potency and binding ability to the SARS-CoV-2 spike protein, as well as other desirable qualities. Using a multi-antibody approach allows for targeting of different parts of the virus and may help protect against multiple viral variants. Regeneron previously used these technologies to rapidly develop a successful treatment for Ebola virus infection, which is currently under review by the U.S. Food and Drug Administration.

The company said they plan to initiate large-scale manufacturing by mid-April with antibody cocktail therapy.

Regeneron is a leading American biotechnology company that invents life-transforming medicines for people with serious diseases.

About Zeibiz 219 Articles
Owner of website.